QUOTE AND NEWS
Benzinga  Jul 14  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it was issued patent number 5749273 from the Japanese Patent Office...
Benzinga  Jun 9  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Dr. Godefridus Peters of the VU University Medical Center, Amsterdam,...
Benzinga  Apr 20  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that it will have two poster presentations at the 2015 American Association...
Benzinga  Mar 20  Comment 
In a report published Friday, MLV & Co analyst Vernon T. Bernardino initiated coverage on Rexahn Pharmaceuticals, Inc. (NYSE: RNN) with a Buy rating and $1.25 price target. In the report, MLV & Co noted, "We initiate coverage of Rexahn...
StreetInsider.com  Sep 25  Comment 
LipoScience, Inc. (Nasdaq: LPDX) 63.2% HIGHER; Lab Corp. (NYSE: LH) and LipoScience, Inc. (Nasdaq: LPDX) announced that they entered into a definitive merger agreement under which LabCorp would acquire LipoScience for a purchase price of $5.25...
StreetInsider.com  Sep 24  Comment 
Rexahn (AMEX: RNN) 11.8% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its drug RX-3117 for the treatment of patients with pancreatic cancer. RX-3117 is a next generation,...
StreetInsider.com  Sep 24  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/UPDATE%3A+Rexahn+Pharma%27s+%28RNN%29+RX-3117+Granted+FDA+Orphan+Drug+Designation/9857256.html for the full story.
Benzinga  Sep 3  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced it has received a notice of allowance from the United States Patent and...
StreetInsider.com  Sep 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rexahn+Pharma+%28RNN%29+Receives+NoA+from+USPTO+Covering+CPMA/9801569.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki